

To: [REDACTED] 5.1.2e [REDACTED] 5.1.2e @minvws.nl]
Cc: [REDACTED] 5.1.2e [REDACTED] 5.1.2e @minvws.nl]
From: [REDACTED] 5.1.2e [REDACTED] 5.1.2e
Sent: Mon 3/22/2021 7:44:42 PM
Subject: Fwd: [EXTERNAL] Re: Confidential - Our concerns re potential trade barriers for Pfizer/BioNTech's COVID19 vaccine
Received: Mon 3/22/2021 7:44:45 PM

Vertrouwelijk - Ter kennisgeving.
 Laat graag weten wanneer je hierover wilt spreken.
 Mvg,
 [REDACTED] 5.1.2e

Begin forwarded message:

From: "[REDACTED] 5.1.2e" <[REDACTED] 5.1.2e @pfizer.com>
Date: 22 March 2021 at 18:03:51 CET
To: [REDACTED] 5.1.2e [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @gmail.com>
Cc: "[REDACTED] 5.1.2e" <[REDACTED] 5.1.2e @pfizer.com>, "[REDACTED] 5.1.2e" <[REDACTED] 5.1.2e @pfizer.com>, "[REDACTED] 5.1.2e" <[REDACTED] 5.1.2e @pfizer.com>
Subject: RE: [EXTERNAL] Re: Confidential - Our concerns re potential trade barriers for Pfizer/BioNTech's COVID19 vaccine

Thanks [REDACTED] 5.1.2e appreciated.
 Let us know if you need any further support or assistance, to support you and Dutch Government on this matter.

From: [REDACTED] 5.1.2e [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @gmail.com>
Sent: 22 March 2021 16:30
To: [REDACTED] 5.1.2e [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @Pfizer.com>
Cc: [REDACTED] 5.1.2e [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @pfizer.com>; [REDACTED] 5.1.2e [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @pfizer.com>
Subject: [EXTERNAL] Re: Confidential - Our concerns re potential trade barriers for Pfizer/BioNTech's COVID19 vaccine

Fully agree.
 Will be supportive.
 [REDACTED] 5.1.2e

On 22 Mar 2021, at 13:57, [REDACTED] 5.1.2e [REDACTED] 5.1.2e <[REDACTED] 5.1.2e @pfizer.com> wrote:

Hi [REDACTED] 5.1.2e

Thank you again for a very productive conversation on Friday afternoon.
 As I shared during our conversation, we are highly concerned regarding the increased rhetoric on trade barriers or export restrictions on COVID19 vaccines.

Per your suggestion, I also wanted to provide some specific information about Comirnaty®, Pfizer/BioNTech's COVID19 vaccine, to better explain what any trade barrier might mean.

Comirnaty® has 280 components, manufactured across 86 different sites, across 19 countries. For example, our Lipid nanoparticles (LNPs) are manufactured in the UK, and our plasmid DNA is manufactured in the USA and they are both critical to manufacture the finished good in Puurs, Belgium. Any export restriction on the final vaccine and any retaliation it might trigger regarding the raw materials or components, could result in Pfizer not being able to produce our vaccine, for Europeans or any other countries.

I also would like to share in confidence that we need to do 41 quality tests for each batch of Comirnaty®. 28 of them do take place on site in Puurs, Belgium and 13 of such tests require us to send batch testing samples to the specialized Pfizer R&D facilities in the USA. Current export notification system by EU do require us to apply for approval for such batch sample exports to USA, and add significant administrative burden and uncertainty on our tightly calibrated supply chains. Additionally, the current regulation was drafted in a way which meant it was open to interpretation. For example, some of our batch samples that needed to be tested in the USA were mistakenly held by customs in February. This is a vital aspect of our quality testing process, and if not resolved, this could have impacted our manufacturing, particularly release of doses for shipment for all patients, including those in Europe. The existing regulation also applies for clinical trial stocks. In other words, our ability to both run clinical trials, and to quality test vaccines for manufacturing in Europe also depends on being able to export outside the EU.

I am sharing all these information in confidence with you. Pfizer is meeting our supply requirements and obligations to the Netherlands, to Europe, and we are continuing to ramp up production. Thanks to these efforts, we were able to expedite 4m doses for March and 10m doses for Q2 2021 for Europe. As Pfizer, we will highly appreciate the political support and voice by yourself, Dutch Government and Dutch Cabinet at European level, for free flow of COVID19 vaccines and components, without any trade barriers. We believe that further restricting exports or vaccine operations in the EU will be to the detriment of all patients. We welcome de-escalation and focusing on solutions. Let me know if we can be any further assistance and support.

Best wishes,

5.1.2e

5.1.2e

Pfizer Netherlands

O: 5.1.2e M: 5.1.2e
E: 5.1.2e [@pfizer.com](mailto:5.1.2e@pfizer.com)

<image001.png>

De inhoud van dit bericht en van eventuele bijlagen is uitsluitend bedoeld voor de geadresseerde(n). Het bericht bevat informatie die confidentieel van aard en/of geprivilegieerd kan zijn. Wanneer u noch de bevoegde ontvanger, noch bevoegd bent namens deze te ontvangen, is het u niet toegestaan dit bericht te kopiëren, te gebruiken of te openbaren aan andere personen. Indien u dit bericht abusievelijk hebt ontvangen verzoeken wij u vriendelijk dit per omgaande aan de afzender te laten weten en vervolgens het bericht te vernietigen.

Pfizer bv, statutair gevestigd te Rotterdam (adres: Rivium Westlaan 142, 2909 LD Capelle aan den IJssel, handelsregisternummer 34087728).

The content of this e-mail and of its possible attachments is intended for the named addressee(s) only. It contains information which may be confidential and which may also be privileged. Unless you are the named addressee or authorised to receive for the addressee you may not copy or use it, or disclose the e-mail or its content to anyone else. If you receive this e-mail in error please notify the originator immediately and then destroy it.